Ipamorelin: Research Profile, Pharmacology, and GH Secretagogue Effects
Ipamorelin is the most selective synthetic GHS-R1a agonist, producing robust GH pulses with minimal cortisol or prolactin elevation. This deep-dive reviews its pharmacology, research data, and why it has become the standard GH secretagogue in research stacks.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide GHS-R1a agonist developed by Novo Nordisk researchers in the late 1990s and first characterised by Raun K et al. (*European Journal of Endocrinology*, 1998) as the first GHRP to produce potent GH release without co-stimulating cortisol, prolactin, or ACTH.
Receptor Pharmacology
Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs through phospholipase C / intracellular calcium mobilisation, triggering immediate GH vesicle exocytosis. Unlike GHRP-2 or hexarelin, it does not produce ACTH/cortisol co-stimulation at any GH-stimulating dose tested.
In Raun K et al.'s direct comparison (rats):
- Peak GH after ipamorelin: ~400 ng/mL
- Cortisol co-release: not measurably elevated above baseline
- Prolactin: unchanged
- Selectivity described as "remarkable" relative to all other GHRPs tested
GH Pulse Kinetics
Ipamorelin produces a clean GH pulse with return to baseline within ~3 hours, mimicking the natural pulsatile rhythm of GH secretion. Johansen PB et al. (*Growth Hormone & IGF Research*, 1999) confirmed in pigs that twice-daily ipamorelin at 200 mcg/kg maintained IGF-1 elevation over 15 days without tachyphylaxis — unlike GHRP-6 at equivalent doses, which showed progressive IGF-1 blunting after day 7.
Synergy With GHRH Analogues
When combined with Sermorelin or CJC-1295 (no DAC), ipamorelin produces 3-5× greater GH output than either agent alone. The combination exploits complementary pathways: GHRH-R (cAMP/PKA, increasing GH gene transcription) + GHS-R1a (PLC/calcium, triggering immediate exocytosis) produce synergistic GH release.
Selectivity vs Other Secretagogues
| Peptide | GH Release | Cortisol | Prolactin | Appetite |
|---|---|---|---|---|
| Ipamorelin | Potent | None | None | Mild |
| GHRP-2 | Potent | Moderate | Mild | Moderate |
| GHRP-6 | Potent | Mild | Moderate | Strong |
| Hexarelin | Very potent | Moderate | Moderate | Mild |
The clean selectivity profile is ipamorelin's defining pharmacological feature and explains why it is the most commonly used GHRP in research protocols where hormonal specificity is required.
Ipamorelin is a research compound not approved for human use.
<!-- deep-links-v1 -->
Related Secretagogue and GH Axis Research
Ipamorelin research is closely connected to the broader secretagogue landscape. GHRP-6, an earlier ghrelin mimetic, provides a pharmacological reference with higher appetite-stimulating activity and stronger cortisol co-secretion. Mod GRF 1-29, the GHRH analogue most commonly paired with ipamorelin in research settings, acts on GHRH receptors to extend and amplify the GH pulse. Tesamorelin offers a clinically validated GHRH comparison with FDA approval data for visceral adiposity. Somatropin (rHGH) is the exogenous GH baseline used in clinical outcome comparisons. Ghrelin, the endogenous appetite hormone, is the native ligand that ipamorelin was designed to selectively mimic. Somatostatin antagonizes GHRH signaling, and understanding its interplay with ipamorelin is central to optimizing pulse timing in research protocols.
About the Author
KnowYourPeptide Research Team
KnowYourPeptide Research Team
Content produced by the KnowYourPeptide research and editorial team. All articles are written from peer-reviewed primary literature and reviewed for scientific accuracy by credentialed researchers and a board-certified physician before publication.
Meet the full editorial teamMedically Reviewed by Dr. Amanda Reid, MD
This article has been reviewed by Dr. Amanda Reid, MD (Board-Certified Internal Medicine), Know Your Peptide Medical Advisor, for scientific accuracy, safety information, and appropriate clinical context. Learn about our review process.